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1. Introduction 
The term "antiphospholipid syndrome" (APS) was coined in the early '80s to describe a 
unique form of acquired autoimmune thrombophilia, with clinical features of recurrent 
thrombosis and pregnancy morbidity, combined with the presence of antiphospholipid 
antibodies (aPL). aPL consist a heterogeneous group of autoantibodies, which recognize 
phospholipid-protein complexes or rather proteins with high affinity for phospholipids, 
such as ǃ2-glycoprotein I (ǃ2GPI) and prothrombin. This heterogeneity reflects the nature of 
the antigen recognized by each antibody and it is expressed with different pathogenic 
mechanisms. Although a broad spectrum of aPL exists, the universally accepted diagnostic 
aPL tests are lupus anticoagulant (LA); anticardiolipin (anti-CL); and anti–ǃ2-glycoprotein I 
antibodies (anti-ǃ2GPI) (Table 1). These autoantibodies interfere with physiological 
mechanisms of coagulation and fibrinolysis, leading the hemostatic balance towards 
coagulation. Moreover, it seems to affect the physiological function of various cells such as 
platelets, monocytes and endothelial cells (EC). However, not all aPL are pathogenic; 
transient increase in aPL during several infections has been observed. Although aPL can 
cause clinical manifestations of almost every organ in the body (e.g. blood vessels, brain, 
kidneys, lungs, gastrointestinal tract, placenta), the common hallmark of the syndrome is 
thrombosis, either arterial, venous or in the microcirculation. 
2. Epidemiology 
2.1 aPL in healthy population and other conditions 
In healthy population, the incidence of aPL ranges from 1 to 5%. It has been shown to 
increase with age and especially with coexistence of chronic diseases [1]. Among various 
studies, there is great variation in the incidence of anti-CL antibodies in apparently healthy 
elderly subjects, ranging from 12 to 64% [2]. The prevalence of anti-ǃ2GPI antibodies is 
calculated at 31.8%. These variations may be attributed to both methodological differences 
and choice of sample population. In general population, aPL are detected in about one out 
of five patients who suffered from cerebrovascular events (strokes) at the age under 50 
years. The clinical suspicion is clearly enhanced in young patients with additional features 
of the syndrome. Moreover, aPL can be detected in various conditions such as infections, 
malignancies, vaccination and use of certain drugs. In these cases, aPL are usually transient, 
low-titre and normally independent of the presence of ǃ2GPI. The prevalence of aPL in 
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healthy obstetric population is difficult to be determined since aPL have been implicated in 
pregnancy morbidity. However, in two studies with large number of healthy pregnant 
women, aPL were identified in 0.7 and 5.3% respectively [3]. It has been reported that aPL 
are detected in 11-29% of women with preeclampsia [4].  
 
Symbol/acronym Description/explanation Definition based on the detection assay 
Anti-CL Anti-cardiolipin  Antibodies detected against cardiolipin-a 
negatively charged phospholipid, which is 
used as antigen in an enzyme linked 
immunosorbent assay (ELISA). These 
antibodies recognize ǃ2GPI which exists in 
abundance in bovine serum; this serum is 
used as a blocking agent (blocks the non-
specific binding sites) in ELISA plates. 
ǃ2GPI binds to cardiolipin. 
Anti-ǃ2 GPI Antibodies recognizing ǃ2 
GPI independently of 
cardiolipin 
Anti-ǃ2GPI antibodies are detected by 
ELISA, but the polystyrene ELISA plates 
have been Ǆ-irradiated and negative 
charges are generated on their surface. 
ǃ2GPI binds to negatively charged 
irradiated plates in the absence of 
cardiolipin and is recognized by the anti-
ǃ2GPI antibodies 
LA Lupus Anticoagulant Antibodies which interfere in vitro with the 
generation of thrombin from prothrombin, 
thus increasing the activated partial 
thromboplastin time (aPTT). The 
prolonged aPTT is not corrected by adding 
normal plasma in the detection system. 
These antibodies disrupt in vitro the 
prothrombinase complex (constituted by 
the activated coagulation factors V and X, 
prothrombin and phospholipids). Kaolin 
clotting time (KCT) and Dilute Russel 
Viper Venom Test (DRVVT) are two other 
ways to measure LA. Antibodies of the LA 
type usually recognize ǃ2GPI or 
Prothrombin. 
BFP-STS & VDRL 
test 
Biological false positive 
serological tests for 
syphilis & Venereal 
Disease Research 
Laboratory test 
Antibodies against 
phospholipids/cholesterol complexes 
Table 1. Classification of antiphospholipid antibodies defined according to detection assay. 
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2.2 aPL in other systemic autoimmune diseases 
APS can occur in association with other systemic autoimmune diseases, particularly 
Systemic Lupus Erythematosus (SLE). About 40% of patients with SLE have aPL, but less 
than 40%of them will eventually have thrombotic events [5]. Particularly, 37% of patients in 
the "Euro-Phospholipid" study was suffering from SLE, while 4% was associated with SLE-
like disease [6]. It is well documented that thrombotic complications appear more frequently 
in patients with SLE and aPL, as compared to aPL positive patients without other systemic 
autoimmune disease[7,8]. The diagnosis of secondary APS clearly leads to a threefold 
increase of miscarriages, especially after the 20th week of gestation [9]. aPL have also been 
detected in other autoimmune diseases, such as rheumatoid arthritis (RA), with a frequency 
up to 28%. 
3. Classification Criteria for APS 
An international consensus statement on the APS classification was published in 1999, after 
the 8th International Symposium on the aPL in Sapporo [10]. The diagnosis of the syndrome 
requires the presence of at least one clinical event and one positive laboratory test for aPL, 
including lupus anticoagulant (LA) or anti-CL antibodies, or both, in medium-high titers, 
detected at least twice within 6 weeks . The classification criteria were revised in 2006, in 
Sidney, Australia [11]. Essentially, the clinical criteria remained unchanged while the 
laboratory criteria were modified in two significant points: (a) the time between two positive 
determinations was extended to 12 weeks and (b) anti-ǃ2GPI antibodies (IgG and IgM) were 
included in the laboratory tests (Table 2).  
After 30 years of intensive clinical and basic research, it is now well documented that LA is 
the strongest predictor of thrombosis [12-14]. Moreover, anti-ǃ2GPI antibodies appear to be 
mainly responsible for the clinical manifestations that characterize the syndrome [15,16]. More 
specifically, a subpopulation of anti-ǃ2GPI antibodies, raised against a cryptic epitope in 
domain I ǃ2GPI (Arg39-Arg43), is highly correlated with clinical events and prognosis of the 
syndrome [17]. Several research groups suggest that patients positive for all three classes of 
antibodies (LA, anti-CL and anti-ǃ2GI) are at the higher risk for venous/arterial thrombosis 
and pregnancy morbidity [18,19]. 
4. Clinical manifestations of APS 
Clinical presentation of APS includes manifestations of various organs and systems, such as 
blood vessels, central nervous system (CNS), skin, kidney, gastrointestinal tract, heart, and 
placenta. The hallmark of the syndrome is thrombosis, either arterial or venous. Unlike the 
strict vaso-specific localization of thrombosis due to congenital thrombophilias (e.g. 
correlation between deficiency of protein C only with venous thromboembolic events), 
thrombosis in APS may occur in any vascular bed [20,21]. This "diffuse" thrombotic 
predisposition clearly indicates a multifactorial influence of autoantibodies in the 
haemostatic system. It is worth noting that thrombotic recurrences tend to occur in the same 
vascular distribution as the original event (i.e., arterial are followed by arterial and venous 
by venous thrombotic events)[22]. Venous thromboembolic events are the most common 
clinical manifestations of APS. The clinical expression of the syndrome can vary from mild 
(mild thrombocytopenia, livedo reticularis, leg ulcers, migraine) to severe (ischemic 
infarctions, recurrent miscarriages, valvular insufficiency) or destructive [multiple organ 
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failure, catastrophic APS (CAPS)]. The clinical spectrum associated with the presence of aPL 
is extensive. The events included in the classification criteria of APS are described in (Table 
3). Some clinical manifestations, such as valvular disease, livedo reticularis, 
thrombocytopenia and neurological manifestations, although not included in the diagnostic 
criteria of the syndrome, are frequently observed in patients with APS [11]. The thrombotic 
etiology for these events does not seem very likely, as they usually do not subside with 
antithrombotic therapy. The simultaneous presence of thrombotic and non thrombotic 
events in patients with APS leads to the logical conclusion that most of the aPL (and 
especially anti-ǃ2GPI antibodies) interfere with many different biological mechanisms. 
Moreover, there is a subset of asymptomatic patients with permanently high titers aPL. 
 
Antiphospholipid antibody syndrome (APS) is present if at least one of the clinical criteria 
and one of the laboratory criteria that follow are met 
Clinical criteria 
1. Vascular thrombosis 
One or more clinical episodes of arterial, venous, or small vessel thrombosis§, in any tissue 
or organ. Thrombosis must be confirmed by objective validated criteria (i.e. unequivocal 
findings of appropriate imaging studies or histopathology). For histopathologic 
confirmation, thrombosis shouldbe present without significant evidence of inflammation 
in the vessel wall. 
2. Pregnancy morbidity 
a. One or more unexplained deaths of a morphologically normal fetus at or beyond the 
10th week of gestation, with normal fetal morphology documented by ultrasound or 
by direct examination of the fetus, or 
b. One or more premature births of a morphologically normal neonate before the 34th 
week of gestation because of: (i) eclampsia or severe preeclampsia defined according 
to standard definitions [11], or (ii) recognized features of placental insufficiency, or 
c. Three or more unexplained consecutive spontaneous abortions before the 10th week 
of gestation, with maternal anatomic or hormonal abnormalities and paternal and 
maternal chromosomal causes excluded. 
Laboratory criteria 
1. Lupus anticoagulant (LA) present in plasma, on two or more occasions at least 12 
weeks apart, detected according to the guidelines of the International Society on 
Thrombosis and Haemostasis (Scientific Subcommittee on LAs/phospholipid-
dependent antibodies)   
2. Anticardiolipin (aCL) antibody of IgG and/or IgM isotype in serum or plasma, 
present in medium or high titer (i.e. >40 GPL or MPL, or >the 99th percentile), on two 
or more occasions, at least 12 weeks apart, measured by a standardized ELISA   
3. Anti-b2 glycoprotein-I antibody of IgG and/or IgM isotype in serum or plasma (in 
titer >the 99th percentile), present on two or more occasions, at least 12 weeks apart, 
measured by a standardized ELISA, according to recommended procedures   
Modified from ref 11 
Table 2. Classification criteria for antiphospholipid syndrome 
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The literature on the clinical manifestations of APS, although extensive, mostly includes a 
large number of case reports. Fortunately, since the beginning of the 21st century, significant 
multicenter studies on large series of patients provide reliable information as to the relative 
frequency of different clinical manifestations of the syndrome [21,23,24]. In a multicenter study 
of 1000 patients with APS, 53.1% of patients had primary APS while 36.2% had secondary 
APS (in association with SLE). The most common manifestations were deep venous 
thrombosis (38.9%), thrombocytopenia (29.6%), livedo reticularis (24.1%), stroke (19.8%) and 
pulmonary embolism (14.1%). Less frequent events included superficial thrombophlebitis 
(11.7%), transient ischemic attacks (11.1%), hemolytic anemia (9.7%) and epilepsy (7%). The 
fetal abortion was the primary event in 14% of female patients.  
4.1 Venous thrombosis 
As mentioned above, deep venous thrombosis is the most frequent clinical manifestation of 
APS. Other vascular sites which may be affected are the larger veins, such as the subclavian, 
the iliofemoral, the upper abdomen, portal vein, the axillary etc. Venous thrombosis has 
been described, with much less frequency, in almost every organ of the body, causing 
related clinical manifestations. Superficial thrombophlebitis, superior vena cava syndrome, 
renal vein thrombosis, adrenal infarction, Addison’s syndrome, Budd Chiari syndrome, 
pulmonary hypertension, due to recurrent pulmonary embolism and diffuse pulmonary 
hemorrhage, due to micro-thromboses are some of the unusual venous thrombotic 
manifestations of the syndrome. Recent meta-analysis regarding the relationship (odds ratio, 
OR) of LA and IgG/IgM anti-CL antibodies with venous thrombosis, concludes that all 
studies report a significant correlation between LA and VTE, with an OR up to 16.2. The 
correlation of anti-CL with VTE is not confirmed [25]. Titers of anti-ǃ2GPI antibodies seem to 
increase the OR for venous thrombosis up to 5 times [26]. 
4.2 Arterial thrombosis 
Arterial thrombosis consists a main clinical feature of APS, but appears less frequently than 
venous [27]. The most common site of arterial thrombosis is the cerebral circulation, usually 
in the form of stroke or transient ischemic attack [21]. Thrombosis of coronary, renal artery or 
the mesentery has also been observed. A multicenter population-based study, which 
examined the risk of arterial thrombosis in patients who were treated with oral 
contraceptives (RATIO study, Risk of Arterial Thrombosis In relation to Oral 
contraceptives), showed that the presence of LA is a major risk factor for arterial thrombosis 
in women under 50 years, while anti-CL and anti-prothrombin antibodies did not increase 
the risk for ischemic stroke or myocardial infarction [28].  
4.3 CNS involvement 
The CNS involvement is co-responsible for high morbidity and mortality of the syndrome, 
with strokes and transient ischemic attack being the most common manifestations [29,30]. The 
neurological manifestations cover a fairly broad clinical spectrum and may include, apart 
from stroke and transient ischemic attack, also Sneddon’s Syndrome, epilepsy, dementia, 
cognitive dysfunction, headaches/migraine, chorea, transverse and spotty myelitis, ocular 
symptoms, Guillain-Barré, psychosis and depression [31]. More specifically, the presence of 
anti-CL antibodies in SLE patients has been associated with cognitive disorders. Similarly, 
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mild cognitive impairment has been recorded in more than 40% of patients with APS and 
focal white matter lesions [32]. 
4.4 Renal involvement 
APS nephropathy is now recognized as a distinct entity from lupus nephritis [33]. The most 
common manifestations of renal involvement are thrombosis or stenosis of renal artery, 
kidney infarction, thrombosis of the renal vein and end-stage renal disease/renal failure [34]. 
Clinically, the so-called APS nephropathy is characterized by positive aPL in conjunction 
with vascular nephropathy, which presents with hypertension, low-grade proteinuria, and 
acute and/or chronic renal failure. The clinical suspicion of this clinical entity should always 
be placed in young patients with renal artery stenosis, high blood pressure and unexplained 
deterioration of renal function. The main histopathological findings are: a) thrombotic 
microangiopathy, as an expression of acute thrombosis, and b) fibrous intimal hyperplasia, 
arteriosclerosis, focal cortical atrophy, arterial and fibrous infarcts, as for chronic vascular 
lesions [34]. The biopsy proven renal damage is significantly correlated with LA, but not 
with anti-CL antibodies. A study from our department showed that patients with APS and 
kidney involvement develop hypertension, elevated serum creatinine levels, characteristic 
findings in renal biopsy as mentioned previously, and factors associated with poor renal 
prognosis [35]. Moreover, a large series of patients demonstrated that APS nephropathy is 
presented in 39.5% of patients with SLE and positive aPL, while only in 4.3% of SLE patients 
without aPL [36]. The APS nephropathy is strongly correlated with LA, anti-CL antibodies 
and livedo reticularis. The prognosis of nephritis in patients with SLE is rather poor in the 
presence of coexisting APS nephropathy. 
4.5 Cardiovascular manifestations 
Cardiac manifestations in APS include valvular disease, acute myocardial infarction (AMI), 
intracardial thrombi, myocardial microthrombosis and valvular lesions similar to Libman-
Sacks endocarditis of SLE [37]. The latter represent the commonest manifestation in APS with 
prevalence up to 38% [38]. The valves of the left ventricle are most frequently involved, with 
mitral impairment observed in the majority of cases. It is well known that patients with 
valvular disease are at higher risk of arterial thromboembolic events [39]. In a multicenter 
prospective study, AMI was the presenting manifestation in 2.8% and reached up to 5.5% 
during the follow-up period [40]. A large prospective study found that high titers of anti-CL 
antibodies are an independent risk factor for AMI or sudden cardiac death [41]. Although 
some studies do not show a correlation between anti-CL and AMI, there should be a 
thorough check for aPL in patients aged under 45 with coronary artery disease or AMI 
without other risk factors.  
4.6 Skin manifestations 
Skin events in APS vary both in form and severity, with livedo reticularis and leg ulcers 
being the commonest [42]. Livedo reticularis is caused by stagnation of blood in dilated 
superficial capillary venules and its prevalence in APS is calculated at 24%, according to the 
study of Cervera et al [43,44]. This lesion represents the first manifestation of the syndrome in 
17-40% of patients. The clinical features of such lesions, although nonspecific, can lead to the 
diagnosis of APS. Typically, the histopathological findings of skin biopsies do not reveal 
evidence of thrombosis (except in the case of CAPS). Livedo reticularis has been 
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characterized as a major risk factor for arterial thrombosis and it is correlated with high 
titers of anti-CL antibodies [45]. Other cutaneous manifestations of the syndrome are leg 
ulcers, superficial thrombophlebitis, necrotizing vasculitis and gangrene. 
4.7 Hematological manifestations 
Several hematological manifestations such as thrombocytopenia, autoimmune hemolytic 
anemia, Evan’s syndrome, bone marrow necrosis and thrombotic microangiopathy have 
been described in APS [46]. Thrombocytopenia, defined by platelet count less than 100-
150x109/L, is found in approximately 20% of patients with primary APS and more than 40% 
of patients with secondary APS in SLE [21,47]. It is usually moderate and does not require any 
medical intervention. The mechanisms that may lead to thrombocytopenia in patients with 
APS are not clear. However, the characteristic combination of thrombocytopenia and 
thrombosis in APS patients suggests that aPL interact with platelets resulting in platelet 
aggregation and thrombosis. The prevalence of autoimmune hemolytic anemia in APS 
patients was calculated at 6.6% to 9.7% [23]. On the other hand, studies confirm the presence 
of aPL in patients with autoimmune hemolytic anemia at a rate ranging from 55 to 72% 
[48]. The pathogenesis of autoimmune hemolytic anemia is unclear. It has been assumed that 
anti-CL antibodies bind directly to the surface of red blood cells of patients with APS and 
hemolytic anemia, although the antigen recognized by aPL has not been identified. 
5. Pathogenic mechanisms of thrombosis 
Significant in vitro and in vivo studies confirm that aPL are pathogenic [49-51]. The exact 
mechanism by which these antibodies participate in the prothrombotic tendency of APS, 
remain to be clearly defined. However, it has been illustrated that the heterogeneity of 
antibodies is associated with multiple mechanisms of action [52]. These include briefly: the 
activation of cellular components (endothelial cells, platelets and monocytes), activation of 
the coagulation cascade, inhibition of the fibrinolytic system, inhibition of natural 
anticoagulant pathways and activation of the complement system. 
5.1 Activation of cellular components 
5.1.1 Activation of endothelial cells 
The interaction of aPL with endothelial cells has until now been in frequent disputes and 
misunderstandings. Regarding the study of endothelium in the pathogenesis of APS, major 
questions have arisen: a) Under what conditions the aPL bind to the surface of endothelial 
cells in vitro and in vivo; b) What molecular structures on the surface of endothelial cells are 
responsible for the binding d) What signaling pathways are activated; Table 4 summarizes 
the effects of aPL on endothelial cells. 
In vitro studies have shown that ǃ2GPI binds to immobilized endothelial cells, and allows 
the anti-ǃ2GPI antibodies to bind to cells and induce a proinflammatory and procoagulant 
phenotype [53]. A clinical demonstration of endothelial dysfunction in APS patients is the 
increased level of circulating endothelial microparticles and endothelial cells in peripheral 
blood [54,55]. In vitro studies have shown that incubation of endothelial cells with aPL and 
ǃ2GPI, induces the expression of significantly higher levels of adhesion molecules ICAM-1, 
VCAM-1 and E-selectin. In addition, production of IL-6 and altered metabolism of 
arachidonic acid, have been demonstrated [56-58]. Animal models suggest that human 
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Clinical and laboratory 
characteristics 
Presence at the 
disease onset n (%) 
Cumulative 
prevalence n (%) 
Thrombophlebitis 28 (20.72) 57 (42.18) 
Peripheral Arterial Thrombotic 
Event 
6 (4.44) 12 (8.88) 
Pericarditis 5 (3.7) 11 (8.14) 
Myocarditis 1 (0.74) 1 (0.74) 
Stroke (arterial) 10 (7.4) 32 (23.68) 
Brain Microinfarcts/TIA  1 (0.74) 14 (10.36) 
Brain Venous Thrombosis 1 (0.74) 1 (0.74) 
Epilepsy/Seizures 2 (1.48) 19 (14.06) 
Diplopia/Οcular disorders 1 (0.74) 23 (17.02) 
Peripheral Neuritis 1 (0.74) 30 ( 22.2) 
Lower Back Pain 1 (0.74)  15 (11.1) 
Headache/Migraine 6 (4.44) 34 (25.16) 
Pleurisy 3 (2.22) 12 (8.88) 
Pulmonary Emboli 7 (5.18) 16 (11.84) 
Pulmonary Arterial 
Hypertension 
1 (0.74) 9 (6.66) 
Nephritis 2 (1.48) 17 (12.58) 
APS associated Nephropathy  1 (0.74) 6 (4.44) 
Budd-Chiari Syndrome 1 (0.74) 1 (0.74) 
Ascites 1 (0.74) 1 (0.74) 
Myalgia 2 (1.48) 9 (6.66) 
Arthralgia 25 (18.5) 67 (49.58) 
Arthritis 9 (6.66) 21 (15.54) 
Livedo Reticularis 2 (1.48) 48 (35.52) 
Ischemic Leg Ulcers 2 (1.48) 5 (3.7) 
Digital Gangrene 1 (0.74) 1 (0.74) 
Maculopapular Rash 3 (2.22) 13 (9.62) 
Malar Rash (Butterfly) 8 (5.92) 21 (15.54) 
Mucosal Ulcers 6 (4.44) 15 (11.1) 
Vasculitis Rash 1 (0.74)  5 (3.7) 
Raynaud 10 (7.4)  34 (25.16) 
Photosensitivity 8 (5.92) 20 (14.8) 
Alopecia 4 (2.96) 22 (16.28) 
Foetal Loss 23 (23) * 40 (40) * 
Chronic Disease Anemia  1 (0.74) 23 (17.02) 
Hemolytic Anemia 2 (1.48) 22 (16.28) 
Thrombocytopenia 5 (3.7) 20 (14.8) 
Leucopenia 1 (0.74)  40 (29.6) 
*percentage (%) out of the total of female patients (N= 100) 
Grika E. –Vlachoyiannopoulos P. submitted  
Table 3. Prevalence of clinical and laboratory characteristics present on the onset of the disease 
as well as during the follow-up of 135 APS patients (89 PAPS, 46 SAPS). The mean (SD) 
disease duration was 8.8 years (5.3) and the mean (SD) duration of follow up 7.55 (4.89) years. 
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1 ǃ 2GPI-dependent increased expression of adhesion molecules (ICAM-1, VCAM-1, E-
selectin) 
2 Increase of synthesis and secretion of pro-inflammatory cytokines (IL-1, IL-6) 
3 Increased tissue factor expression/upregulation of  tissue factor  mRNA 
4 Increase of endothelin-1 levels  
5 Induction of apoptosis 
Table 4. The effects of aPL antibodies on endothelial cells 
polyclonal and monoclonal aPL activate endothelium and enhance clot formation in vivo 
[50,59]. Studying the effect of aPL in mice with genetic deletion of ICAM-1, E-selectin and P-
selectin, it was demonstrated that aPL-mediated endothelial activation depends on a 
considerable extent by these molecules [60-62]. Some studies suggest the presence of elevated 
levels of soluble adhesion molecules and soluble cytokines in patients with aPL and history 
of thrombosis [63]. Pierangeli et al. examined the pathogenic properties of human anti-CL 
antibodies in vivo and in vitro. The researchers used an in vivo model of thrombosis in 
mouse femoral vein. It turned out that antibodies caused leukocyte adhesion to endothelial 
cells of the microvasculature and increased the expression of adhesion molecules (e.g. 
VCAM-1). Among the proposed mechanisms, which explain the prothrombotic and 
proinflammatory properties of aPL, an increased expression of tissue factor (TF) is included. 
Data on the increase in TF expression in patients with APS is supported by several 
researchers. Typically, Zhou et al. demonstrated that IgG from patients with APS increases 
the expression and function of TF in monocytes [64]. Moreover, they described increased 
levels of soluble TF (sTF) in the peripheral blood of patients with a history of thrombosis 
and aPL. 
The study of the endothelium clearly indicates the potentially beneficial effect of statins in 
the therapeutic approach of patients. Meroni et al. demonstrated that fluvastatin inhibits the 
expression of adhesion molecules and IL-6 by endothelial cells [65]. Very recently, proteomic 
study of monocytes and endothelial cells in patients with APS who received fluvastatin for 
one month, confirmed a significant reduction in the expression of TF, PAR-1, 2 and VEGF, 
which is associated with inhibition of the p38MAPK and NF-kB pathway [66]. Furthermore, 
Shoenfeld et al, based on the immunoregulatory and possibly antithrombotic effect of 
vitamin D, studied the serum levels of vitamin in patients with APS and its in vitro effects in 
HUVEC. It was shown that ~ 50% of patients had vitamin D deficiency (<15ng/ml) which 
correlates with thrombotic complications and other clinical manifestations of the syndrome 
(neurological, ocular, livedo reticularis and skin ulcers). In vitro, vitamin D seems to 
suspend the anti-ǃ2GPI-induced expression of TF [67]. 
The role of anti-endothelial antibodies, especially of anti-HSP60, in the mechanism of 
thrombosis was studied in LA positive patients with secondary APS [68]. These antibodies 
induce endothelial apoptosis and seem to be associated with increased incidence of 
thrombosis. The researchers suggest that anti-HSP60 bind to the surface of EC and induce 
expression of anionic phosphatidylserine, thus providing a target for aPL binding and 
promotion of a thrombotic phenotype. 
The exact nature of aPL- receptors on the surface of endothelial cells remains obscure and is 
a key subject of current research. Initially, several studies have suggested the simple 
recognition of ǃ2GPI, bound to the surface of endothelial cells (by the domain V), by anti-
ǃ2GPI antibodies. This observation emerged from the crystallographic study of ǃ2GPI. This 
glycoprotein is a single-chain polypeptide chain composed of five domains (I-V), 
comprising patterns of the complement control protein family (sushi domains). All domains 
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resemble each other, except for domain V that contains an additional carboxy- loop with 
positively charged amino acids lysine. From the crystal structure of human ǃ2GPI, it was 
showed that the positively charged region interacts electrostatically with negatively charged 
phospholipids. Furthermore, a partially hydrophobic loop of the molecule has the ability to 
enter the phospholipid bilayer and is involved in cell binding of ǃ2GPI [69]. Later, Zhang et 
al. demonstrated that ǃ2GPI binding to endothelial annexin A2 promotes the activation of 
endothelium by anti-ǃ2GPI antibodies, possibly through a mechanism of multiple 
connections (cross linking), thus inducing a procoagulant phenotype [70]. To note that 
annexin A2 lacks intracellular region and possibly a second adaptor protein participates in 
intracellular signal transduction. There is evidence that specific antibodies against annexin 
A2, regardless of aPL, have been detected in plasma from APS patients and seem to 
correlate with thrombotic events. These antibodies are able to activate EC in a manner 
similar to anti-ǃ2GPI antibodies [71]. Besides annexin A2, various members of Toll-like 
receptors (TLRs) family have been proposed as potential receptors of ǃ2GPI/anti-ǃ2GPI 
complexes on the surface of endothelial cells. Several data suggest the involvement of TLR-4 
in aPL-mediated activation of endothelial cells. An important study shows the activation of 
the molecular pathway of MyD88 (Myeloid Differentiation factor 88), which is associated 
with TLR-4 - a receptor of bacterial endotoxin or lipopolysacharide (LPS), by anti-ǃ2GPI 
antibodies [72]. Binding of LPS with TLR-4 triggers the nuclear translocation of NF-kB, the 
p38MAPK phosphorylation and other intracellular events that lead to the expression of pro-
inflammatory cytokines, adhesion molecules and TF [73]. Fischetti et al. showed that the in 
vivo formation of complexes ǃ2GPI/anti-ǃ2GPI on the endothelial surface induces the 
development of thrombus, only under the influence of LPS [74]. In similar results, concerning 
the requirement of a priming factor, conclude several in vivo animal models of thrombosis, 
which require either photochemical or mechanical injury of the vessel so that the aPL can 
exert their thrombotic properties. It is not clear why the formation of anti-ǃ2GPI/ǃ2GPI 
complexes on the endothelial surface cannot induce thrombosis without a priming factor 
[75]. It is generally accepted that other molecules (not specified so far) could act as protein 
receptors for ǃ2GPI, since the glycoprotein lacks a recognized specific cell receptor. It is 
assumed that ǃ2GPI binds to endothelial surface via a "multi-receptor" and the molecular 
signaling is initiated immediately upon binding of specific antibodies. 
The study of signal transduction in aPL-mediated endothelial activation continues to be an 
important area of research. As it was originally shown, there is an increased expression of 
adhesion molecules by endothelium in vitro. Nowadays, several studies confirm the 
involvement of NF-kB nuclear translocation and phosphorylation of p38MAPK in, aPL-
mediated, induction of transcription, expression and function of TF in endothelial cells and 
the production of proinflammatory cytokines (IL-6 and IL-8). 
5.1.2 Activation of platelets 
The thrombophilic tendency in combination with the observation that thrombocytopenia is 
a frequent manifestation in APS, led early on the assumption that platelet activation is an 
important factor in the pathogenesis of the disease [52]. It should be noted that the study of 
platelet as "experimental model" has some peculiarities: platelets as anucleated cell 
fragments cannot be cultivated in vitro, or studied by techniques of recombinant DNA and 
on the other hand, unlike endothelial cells, platelet samples can be purified in the absence 
heparin, leaving unaffected the ǃ2GPI interaction with platelet membranes [76]. Several 
studies demonstrate platelet activation and aggregation by aPL, both in vitro and in vivo 
[77,78]. Figure 1 summarizes the main pathogenic effects of aPL in platelets. It has been  
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Fig. 1. A synopsis of the major and well characterized thrombogenic mechanisms of 
antiphospholipid (anti-ǃ2GPI) antibodies: Pre-existing anti-ǃ2GPI, probably under a second 
hit, activate components of innate immunity such as complement, endothelial cells, 
monocytes (not depicted) and platelets, as well as the coagulation system. More specifically, 
as shown by in vitro experiments, dimmers of ǃ2GPI anchored to negatively charged 
phospholipids and TLR-4 are recognized by anti-ǃ2GPI antibodies; then, P38-MAPK 
mediated endothelial cell activation takes place as depicted by ICAM-1, VCAM-1, E-selectin 
IL-1,-6,-8 and TF expression which change the phenotype of endothelial cells to a pro-
coagulant form. On the other hand, dimmers of ǃ2GPI induced, either, through ǃ2GPI 
interaction with apo-ER2’, or with GPIba, or with PF4 tetramers, activate platelets towards 
aggregation and release of PF4 and thromboxan B2. Coagulation-fibrinolysis imbalance is 
induced by the mechanisms depicted in the upper left panel. 
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demonstrated that aPL cannot bind to the surface of "intact" platelets, while they have the 
ability to bind to platelets with exposed negatively charged phospholipids in their 
membranes. Subactivating priming by known agonists, leading to phosphatidylserine 
exposure on the outer membrane seems to be a prerequisite for aPL to exert their pathogenic 
effects. One significant indication of platelet activation was the observation that patients 
with aPL and positive LA had increased urinary excretion of Thromboxane B2 (TXB2), a 
platelet metabolite secreted upon activation. Furthermore, purified F (ab ') 2 antibody 
fragments from the same patients, caused increased platelet aggregation and release of 
serotonin in the presence of low doses of thrombin. 
A second indication of impaired platelet function in APS, is the observation that 
approximately 40% of patients show prolonged bleeding time, without accompanying 
bleeding tendency [79]. This assay depends only on primary hemostasis and thus is 
considered the classic test for the assessment of platelet function. Strong evidence of aPL-
induced platelet activation is the enhanced expression of platelet membrane glycoproteins, 
particularly GPIIb-IIIa (fibrinogen receptor, critical in platelet aggregation) and GPIIIa [80]. 
More recently, Pierangeli et al. showed that in mice with genetic deletion of GPIIb-IIIa, 
passive immunization with aPL did not increase clot formation [81]. It has been also shown 
that blood clots are reduced in vivo, in mice that had been injected with monoclonal anti-
GPIIb-IIIa antibodies. The possibility to include this type of inhibitors for the treatment of 
thrombotic events in patients with APS has not yet been confirmed. 
A recent suggestion regarding platelet activation derived from the observation that patients 
with SLE and anti-ǃ2GPI antibodies showed increased plasma levels of active von 
Willebrand factor (vWF), leading to platelet aggregation. It is assumed that under normal 
circumstances, ǃ2GPI binds vWF, inhibiting its ability to promote adhesion and platelet 
aggregation, whereas in the presence of anti-ǃ2GPI antibodies this anticoagulant effect is 
inhibited [82].  
The activation of platelets by aPL, in vivo, has been supported by several groups. Joseph et 
al. studied in vivo the extent of platelet activation from patients with primary or secondary 
APS and SLE, using flow cytometry (FACS) and ELISA. They showed evidence of platelet 
activation as a significant increase in CD63 (a lysosomal membrane protein, which moves to 
the cell membrane after activation), increased binding of PAC-1 (a monoclonal IgM 
antibody against GPIIa-IIIb), the formation of platelet-leukocytes complexes and increased 
soluble p-selectin in patients’ plasma [83]. Jankowski et al., studying a photochemically-
induced thrombosis rat model, demonstrated that anti-ǃ2GPI monoclonal antibodies with 
LA activity induced the formation of stable thrombi and large aggregates [51]. 
So far, two receptors have been proposed as mediators of platelet activation by aPL: a) the 
receptor of apolipoprotein E2' (apoER2') and b) glycoprotein GPIba (subunit of the platelet 
receptor GPIb/V/IX), which binds multiple ligands, including vWF. Involvement of 
apoER2' emerged from the research group of De Groot. They constructed chimeric dimers of 
ǃ2GPI, which mimic the properties of anti-ǃ2GPI/ǃ2GPI complexes and showed an increase 
in the degree of platelet aggregation and adhesion to collagen [84]. The dimerization of the 
protein is of major importance, as monomeric ǃ2GPI does not induce the same result. The 
researchers demonstrated by co-immunoprecipitation that dimeric ǃ2GPI interacts with 
apoER2', which mediates the activation of platelets and the production of thromboxane. The 
specific inhibition of apoER2' by a specific monoclonal antibody resulted in reduced 
adhesion of platelets to collagen [85]. The role of apoER2' was recently investigated in an 
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animal model of thrombosis. Passive immunization of apoER2'-/- mice with aPL purified 
from patients or monoclonal anti-ǃ2GPI or ǃ2GPI chimeric dimers, caused significantly 
reduced clots and reduced TF expression of vascular cells and macrophages, compared with 
immunization of control mice [86]. The role of GPIba as a ǃ2GPI-receptor and potential 
mediator of platelet activation has been studied by in vitro binding assays and selective 
inhibition using specific antibodies [87]. It appeared that GPIba was able to bind directly 
ǃ2GPI, suggesting a new mediator in platelet activation and thromboxane production by 
anti-ǃ2GPI antibodies. It is well established that the intracellular signaling triggered by 
ǃ2GPI/antiǃ2GPI complexes in platelets involve the phosphorylation of p38MAPK which 
leads to activation of cytoplasmic phospholipase A2 (cPLA2), and ultimately the production 
of TXB2. However, these events are quite downstream in the intracellular cascade and 
several efforts have been undertaken to reveal more detailed information regarding the 
molecular intracellular events [88]. 
5.1.3 Activation of monocytes 
Activation of monocytes by aPL has been extensively studied. The main findings include an 
increase of TF expression [89] and activity as well as the increased production of 
proinflammatory cytokines. The proposed ǃ2GPI-receptors mediating monocyte activation 
are the members of toll-like receptors, TLR-2 and TLR-4, ApoER2' and annexin A2 [90-92]. 
Although annexin A2 lacks intracellular domain, its involvement is strongly supported by 
genetic modification experiments (knockdown). Therefore, it has been suggested that an 
additional adaptor protein should participate in the interaction. 
5.2 Disruption of coagulation–fibrinolysis balance 
5.2.1 Enhanced coagulation 
It is assumed that although aPL cause delayed clotting times in vitro, these antibodies exert 
procoagulant effects in vivo, with accelerated thrombin formation. The exact pathogenic 
involvement of aPL in the coagulation cascade remains obscure. Apart from the aPL-
mediated increase of tissue factor (TF) expression and activity by endothelial cells and 
monocytes, which has been proven by in vivo models, the direct role of aPL on coagulation 
events is controversial. Autoantibodies against thrombin have been detected in a subgroup 
(up to 43%) of patients with APS [93]. However, after the description by Krilis et al. of the 
possible interaction between ǃ2GPI and thrombin, the results which support the presence of 
distinct antibodies against thrombin must be critically re-evaluated [94]. As mentioned 
above, the effects of LA are caused by either anti-ǃ2GPI/ǃ2GPI complexes, by competitively 
inhibiting the formation of prothrombinase complex in vitro, or by anti-prothrombin (PT) 
/prothrombin complexes [15]. It has been supported by several studies that although anti-PT 
antibodies are involved in the activity of LA, these antibodies by themselves are not 
associated with thrombosis. A recent multicenter study, completed in 2010, which included 
patients with APS and LA, concludes that 26% of patients were positive for anti-PT 
antibodies without any apparent correlation with clinical features of the syndrome [95]. 
Although initially coagulation factor XII was seen as a component of intrinsic coagulation 
pathway, it is now accepted that this factor has a more significant role in intrinsic 
fibrinolysis. Low plasma levels of factor XII in conjunction with presence of aPL has been 
described. Under current circumstances, the deficiency of factor XII does not cause bleeding 
but only prolonged aPTT, which can be taken as an expression of LA. This deficiency can 
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participate in thrombotic events due to its role in fibrinolysis. It has been shown that anti-
ǃ2GPI antibodies inhibit the activation of factor XII, but at high concentrations of antibody 
the opposite effect was observed. On the other hand, when the plasma is enriched with 
ǃ2GPI and excess of negatively charged phospholipids, there is again a reduction in the rate 
of production of activated ΧIIa [96]. Presence of autoantibodies to factor XII is associated 
with LA and appears to be distinct from anti-PT antibodies [97,98]. The presence of these 
antibodies leads to acquired deficiency of factor XII and presents a statistically significant 
association with recurrent fetal abortions in APS. 
5.2.2 Impaired fibrinolysis 
Research data suggest that impaired fibrinolysis may contribute to the thrombophilic 
tendency in APS [97,99-103]. Independent studies have shown an increased activity of 
plasminogen activator inhibitor-1 (PAI-1) and reduced tissue plasminogen activator (tPA) 
following venous obstruction in patients with APS. Another possible mechanism suggested 
that elevated levels of lipoprotein (a) in plasma of patients, which shares structural 
homology with plasminogen, could compete for binding to fibrin and interfere with 
plasmin-mediated degradation of fibrin [104].  Recent studies revealed plasmin as a potential 
antigen in APS and observed that one out of four patients had antibodies to plasmin, which 
potentially interfere with fibrinolysis. Furthermore, binding of tPA by some aPL with 
subsequent inhibition of plasminogen activation has been reported [105-107].  
ǃ2GPI has also been suggested to have a direct role in fibrinolysis, through direct interaction 
with components of plasminogen activation. It has been shown that ǃ2GPI blocks the PAI-1-
mediated inhibition of tPA in a dose dependent manner and that aPL prevent this inhibitory 
effect of ǃ2GPI.  In addition, monoclonal anti-ǃ2GPI antibodies in the presence of ǃ2GPI 
cause reduced endogenous fibrinolytic activity, even in the presence of excess clotting factor 
XIIa. Overall, these data indicate that aPL inhibit both endogenous and exogenous 
fibrinolysis. It has been supported that nicked ǃ2GPI by plasmin, in the lysine-rich amino 
acid chain of domain V, has the ability to bind plasminogen and inhibit the formation of 
plasmin [108,109]. Recent data also give a role to ǃ2GPI and regulation of the fibrinolytic 
system, showing that ǃ2GPI interacts with tPA and causes tPA-dependent activation of 
plasminogen and that this process is inhibited by the presence of anti-ǃ2GPI antibodies [110]. 
The role of annexin A2 in the mechanism of fibrinolysis is also interesting. Apart from this 
role as endothelial receptor of ǃ2GPI/anti-ǃ2GPI complexes, it is known that annexin A2 
induces fibrinolysis by binding tPA and plasminogen. Autoantibodies against annexin A2 
have been reported in patients with APS and appear to correlate with a history of 
thrombosis. These antibodies inhibit the ability of annexin A2 to induce tPA-mediated 
plasminogen activation and to inhibit fibrinolysis on the surfaces of the EC. 
5.2.3 Resistance to natural anticoagulants 
The protein C pathway is the most important natural anticoagulant pathway, activated in 
the presence of low concentrations of thrombin. The activated protein C (activated protein 
C, APC) exerts its anticoagulant effect through proteolytic inactivation of coagulation factors 
V and VIII. Apart from the mutation FV Leiden, the resistance in activated protein C activity 
(APC resistance, APCR) is associated with the occurrence of thrombosis in patients with 
APS and LA. The percentage of patients with aPL and APCR ranges between 17-75%. In a 
recent study, APCR was found in 44% of anti-CL/anti-ǃ2GPI positive patients and in 55% of 
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anti-PS/anti-PT positive patients [111-114]. Indeed, both anti-PT and anti-ǃ2GPI antibodies 
assert to cause APCR [115]. These antibodies reduce the APC activity through competition 
with the latter for binding to phospholipid surfaces. Another possible mechanism through 
which aPL could cause APCR is the direct interaction between ǃ2GPI and APC [116]. It has 
been shown that ǃ2GPI interact directly with the APC, especially in the presence of anti-
ǃ2GPI antibodies, and therefore inhibits its activity. Furthermore, aPL with an affinity for 
proteins C and S have been described in APS patients with protein C or/and S deficiency. 
Cross-reactivity between ǃ2GPI and APC, indicating that several anti-ǃ2GPI antibodies 
recognized APC and vice versa, has also been proposed [117]. Protein C and/or S is 
associated with about five times increased risk of thrombosis, depending on severity of 
deficiency.  
Annexin A5 is a plasma protein with high affinity to anionic phospholipids, thereby creating 
an anticoagulant "shield" in vascular cells and platelets. Rand et al. suggested that aPL could 
induce thrombosis and pregnancy morbidity, by competing with annexin A5 for binding to 
cell surfaces, thereby reducing its anticoagulant properties. However, it must be clarified 
whether this annexin A5 "shield" exists in vivo, as annexin A5 -/- mice showed no specific 
phenotype [118,119]. 
5.3 Activation of innate immunity/ complement activation 
Complement activation appears to have a key role in the thrombophilic diathesis of APS. 
The involvement of complement was first suggested by the observation of increased 
activated complement components in plasma of patients with APS and history of 
thrombosis [120]. As mentioned above, aPL induce a proinflammatory and procoagulant 
phenotype in endothelial cells, monocytes and platelets. It is also well documented that 
activated complement components are able to bind and activate inflammatory cells and 
endothelial cells, either directly through C5b-9 membrane attack complex complex (MAC), 
or through effects mediated by C5a receptor. Furthermore, endothelial cells release TF upon 
activation by anaphylatoxin C5a. In an in vivo model of surgically induced thrombosis in 
mice prior to aPL injections, Pierangeli et al. demonstrated that complement activation plays 
an important role in the induction and stabilization of thrombosis and adhesion of 
leukocytes to endothelial cells. Mice with genetic deletion of the complement components 
C3, C5, or C5a receptor were resistant to aPL-induced thrombophilia [75,121,122]. Another in 
vivo study, with rats pretreated by intraperitoneal injection of bacterial LPS and later(after a 
few hours) injected with polyclonal IgG antibodies from patients with APS, concludes that 
thrombotic manifestations were mainly depended on the activation of factors C5 and C6 [74]. 
Therefore, it turns out that complement activation significantly participates in the 
pathophysiology of thrombosis in APS.  
It remains unclear why only some people with aPL develop clinical manifestations of 
disease. It has been argued by several researchers that the activation of innate immunity 
plays a critical role in two separate stages: a) the "immune" phase, critical for aPL 
production and b) the "pathological "phase, in which autoantibodies become involved in the 
induction of thrombosis [123]. According to this model, aPL alone is insufficient to cause 
thrombosis and thus requires the concomitant triggering of innate immunity (e.g., a ligand 
for TLRs). During those two phases, the innate immunity can be triggered by various stimuli 
such as trauma, infection, inflammation or ischemia. 
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5.4 Controversial issues in the thrombogenic properties of aPL-  A novel mechanism 
for platelet activation involving β2GPI/PF4 complexes 
Despite the clinical diversity (several manifestations with thrombotic or non-thrombotic 
etiology) and laboratory heterogeneity (autoantibodies recognizing many different proteins) 
of APS, it is accepted that only anti-ǃ2GPI antibodies are responsible for the clinical 
presentation of the syndrome [16]. More specifically, a subpopulation of anti-ǃ2GPI antibody 
against a cryptic epitope (Arg39-Arg43) in domain I of ǃ2GPI, which is highly correlated 
with clinical symptoms and prognosis of the syndrome, has been identified [17]. 
Undoubtedly, ǃ2GPI has an important role in the pathophysiology of APS, yet not entirely 
clear even after 30 years of intensive research [124]. So far, the best explanation for the role of 
ǃ2GPI is that anti-ǃ2GPI in APS induce new functions to the glycoprotein. 
The newest trend in the study of ǃ2GPI, oriented to reveal conformational changes and / or 
post-translational modifications of the molecule, which are induced by specific conditions 
and appear to be associated with the pathogenesis of APS. Therefore, while monomeric 
ǃ2GPI (due to lack of specific cellular receptor) binds with low affinity to cell membranes, in 
the presence of anti-ǃ2GPI autoantibodies and upon induction of conformational changes, 
becomes a "sticky" protein that can easily bind to different cellular receptors. So far, two 
responsible factors for such tertiary variations have been suggested: the anionic 
phospholipids and anti-ǃ2GPI antibodies. Very recently, it has been demonstrated that 
ǃ2GPI can exist in two different conformations, a circular and a stretched one. In circulation, 
the glycoprotein lies with the circular conformation and adopts a stretched structure after 
interaction with autoantibodies [125]. The researchers propose that this change could lead to 
the exposure of a "recognition pattern", which explains why the protein interacts with many 
different protein receptors. On post-translational modifications of ǃ2GPI, a large multicenter 
retrospective study was recently published, which concludes that in plasma of APS patients 
the proportion of oxidized form of ǃ2GPI predominates [126]. It becomes clear that ǃ2GPI is 
an enigmatic protein with significant "reserve" of new structures and functions that are 
induced after specific stimuli. 
An important indication about the biology of ǃ2GPI and the mechanisms of action of anti-
ǃ2GPI is the observation that the dimerization of the molecule on the surface of cell 
membranes is a critical step to initiate cellular activation. It was shown that the chimeric 
dimers of ǃ2GPI have the ability to bind and activate platelets, even in the absence of anti-
ǃ2GPI antibodies [84]. Of course, the dimerization of ligands occurs in many known 
interactions with cellular transmembrane receptors. In most cases however, the dimerization 
of the ligand is induced by the transmembrane receptor, which has not been proven in the 
case of ǃ2GPI. 
In vivo models of passive or active immunization with purified antibodies or ǃ2GPI from 
APS patients have demonstrated a clear direct relationship between aPL and the increased 
risk of thrombosis and fetal abortion [51,127,128]. Although the exact pathogenetic mechanisms 
have not been clarified, the involvement of cellular activation (EC, platelets and monocytes) 
is now well-documented. One of the most critical questions in the literature is to identify the 
main cellular receptors through which anti-ǃ2GPI/ǃ2GPI complexes exert their pathogenic 
effects. As presented in this review, several possible receptors have been proposed and 
nowadays, the research is evolving towards the identification of important ones and their 
exact role. 
Our research towards this objective was based to a null hypothesis: platelet membrane 
proteins, which selectively bind to a ǃ2GPI-affinity column, will be those that potentially 
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interact with ǃ2GPI in vivo35. Attempt was made to minimize nonspecific interactions: on 
the one hand, by the effect of neuraminidase on platelets, to remove large sialic groups 
from surface glycoproteins and on the other hand, by the purification of platelet 
membranes and subsequent extraction of membrane proteins. The study highlighted 
platelet factor 4 (PF4) as the dominant ǃ2GPI-binding protein, after protein identification 
by mass spectroscopy. The interaction was studied by analytical methodology and 
confirmed by size exclusion chromatography, which illustrates the composition and 
stoichiometry of complexes. The important point of interaction is that PF4 contributes to 
the natural dimerization of ǃ2GPI, enhancing the recognition of low-affinity anti-ǃ2GPI 
antibodies, which in turn further stabilize the entire complex. With in silico approach, 
molecular dynamics interface suggested that the interaction consists of electrostatic 
interactions between the positively charged surface of the PF4 tetramers and negative 
amino acids in domains III-V of ǃ2GPI, enhanced by the formation of hydrogen bonds. It 
is worth noting that in the proposed structure of the complex, the critical epitopes in 
subunit I of ǃ2GPI are arranged in such a geometric conformation that fits perfectly with 
the geometry of two F(ab') fragments of an antibody. 
The functional significance of the formed ǃ2GPI/PF4 complexes studied both at the level of 
recognition by anti-ǃ2GPI antibodies, and in the induction of platelet activation. The study 
of the antigenicity of ǃ2GPI indicates that the sera of patients with APS recognize 
ǃ2GPI/PF4 complexes more powerful than ǃ2GPI alone. Moreover, the results of this study 
support the phosphorylation of platelet p38MAPK and production of thromboxane B2 
(TXB2) by anti-ǃ2GPI/ǃ2GPI/PF4 complexes, after pretreatment of platelets with 
suboptimal doses of thrombin. The coexistence of anti-ǃ2GPI and ǃ2GPI seemed to be a 
prerequisite for p38MAPK phosphorylation, while the anti-ǃ2GPI/ǃ2GPI/PF4 complexes 
significantly enhance this effect.  
These experimental data combined with literature information, on the importance of 
conformational changes of ǃ2GPI and on the necessity of ǃ2GPI dimerization, leads to the 
following logical model: the binding of ǃ2GPI by PF4 tetramers result to the natural 
dimerization of ǃ2GPI, which is crucial for interaction with phospholipid surfaces and could 
also contribute to the induction of conformational changes, thereby revealing cryptic 
epitopes of domain I. The latter is consistent with the finding of the stronger recognition of 
complexes from patients’ antibodies.  
An interesting observation that arose while guided the study was the known involvement of 
PF4 in the pathogenesis of heparin-induced  thrombocytopenia and thrombosis syndrome 
(HITT) [129,130]. Given the clinical similarities of two immunologically-mediated 
thrombophilic conditions, APS and HITT, we recommend PF4 as a "common denominator" 
of their pathogenesis. One distinguishing point that emerged from this work is that while in 
HITT, platelet activation induced by heparin/PF4/HITT-antibodies complexes is mediated 
primarily by Fc fragments of antibodies and stimulation of FcgRIIa receptor, unlike in APS 
the effects of ǃ2GPI/PF4/anti-ǃ2GPI complexes on platelet activation is independent of the 
Fc fragments of the antibodies [35]. 
In summary, our study describes for the first time a new interaction between ǃ2GPI and 
PF4. The main significance of this interaction is the stabilization of dimeric structures of 
ǃ2GPI upon interaction with PF4, which facilitates the recognition by specific antibodies. 
The formation of anti-ǃ2GPI/ǃ2GPI/PF4 complexes induces platelet activation, mainly 
through the F (ab ') 2 fragments of specific antibodies. 
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5.5 Conclusions 
APS is an autoantibody mediated thrombophilia induced by antibodies recognizing 
phospholipid binding proteins, mainly ǃ2GPI and prothrombin. The mechanisms by which 
these antibodies induce thrombosis are now beginning to be understood and involve 
imbalance of coagulation-fibrinolysis, as well as platelet, endothelial cell and monocyte 
activation towards coagulation. The cellular activation requires dimerization of ǃ2GPI as 
well as intracellular domains possessing adaptor proteins on the cell surface. The most well 
characterized ones are the apoER2’ and the GPIba (subunit of the platelet receptor 
GPIb/V/IX), while Annexin A2 and the receptors TLR-2 and -4 have also been implicated in 
the procoagulant process by some researchers. PF4 is a CXC-chemokine produced by 
platelets and monocytes; PF4 spontaneously forms tetramers in solution and these tetramers 
possess sites available for binding of 2 molecules of ǃ2GPI in a way that PF4 favors a natural 
dimerization of ǃ2GPI, which is then rather accessible for binding by the anti-ǃ2GPI 
antibodies. The anti-ǃ2GPI/ǃ2GPI/PF4 complexes are immunogenic and thrombogenic, at 
least by activating platelets. 
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